Published in Clin J Am Soc Nephrol on April 10, 2014
Independent Role of Underlying Kidney Disease on Renal Prognosis of Patients with Chronic Kidney Disease under Nephrology Care. PLoS One (2015) 0.80
Inhibition of cyst growth in PCK and Wpk rat models of polycystic kidney disease with low doses of peroxisome proliferator-activated receptor γ agonists. J Transl Int Med (2016) 0.75
Patient Survey of current water Intake practices in autosomal dominant Polycystic kidney disease: the SIPs survey. Clin Kidney J (2017) 0.75
Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2012) 9.88
Autosomal dominant polycystic kidney disease. Lancet (2007) 8.55
Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2010) 5.50
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84
The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A (2006) 4.56
Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med (2010) 4.36
Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med (2013) 3.83
Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med (2003) 3.78
Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med (2008) 3.53
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47
Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med (2004) 3.09
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol (2005) 2.92
The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med (1990) 2.82
Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol (2006) 2.77
Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol (2007) 2.71
Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology (2006) 2.68
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol (2005) 2.66
Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol (2010) 2.42
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2009) 2.33
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int (2005) 2.32
Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant (2005) 2.09
Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol (2009) 2.02
Cyst decompression surgery for autosomal dominant polycystic kidney disease. J Am Soc Nephrol (1992) 1.68
Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. Nephrol Dial Transplant (2012) 1.61
The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol (2010) 1.59
Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2009) 1.39
Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol (2013) 1.33
A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol (2009) 1.31
Cyclic nucleotide signaling in polycystic kidney disease. Kidney Int (2009) 1.09
Treatment strategies and clinical trial design in ADPKD. Adv Chronic Kidney Dis (2010) 1.05
Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2014) 1.05
Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis (2010) 1.04
Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease. Curr Opin Nephrol Hypertens (2013) 0.91
Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study. Clin J Am Soc Nephrol (2014) 0.90
Renal disease progression in autosomal dominant polycystic kidney disease. Clin Exp Nephrol (2012) 0.88
Therapy for polycystic kidney disease? It's water, stupid! J Am Soc Nephrol (2007) 0.86
Effect of somatostatin on vasopressin-induced antidiuresis and renal cyclic AMP of rats. Miner Electrolyte Metab (1982) 0.84
Renin-Angiotensin-aldosterone system in autosomal dominant polycystic kidney disease. Curr Hypertens Rev (2013) 0.80
Sirolimus therapy for patients with adult polycystic kidney disease: a pilot study. Transplant Proc (2009) 0.79
mTOR inhibitors and autosomal dominant polycystic kidney disease. N Engl J Med (2011) 0.79
Molecular genetics of autosomal dominant polycystic kidney disease. Clin Invest Med (2003) 0.78